Lisata Therapeutics Acquired by Kuva Labs | Healthcare M&A Deal

Kuva Labs has agreed to acquire Lisata Therapeutics, a healthcare services other business in Delaware, for $0.001. Lisata Therapeutics is a healthcare company with common stock listed under CUSIP 128058302, and Kuva Labs acquisitions are focused on expanding healthcare M&A exposure. The planned merger acquisition involves Kuva Acquisition Corp., a direct wholly owned subsidiary of Kuva Labs Inc., pursuing a strategic acquisition of all issued and outstanding shares. The deal is structured as a strategic acquisition and merger acquisition, with a Schedule TO tender offer statement filed as preliminary communications ahead of the planned tender offer.